Saving lives through our platform technology, making cost-effective bio industrials and therapeutics available for everyone, everywhere.
About Us
Our Mission
We want to disrupt the poultry E. coli vaccine industry being market leading within the next 5-10 years.
Gefjon Pharma has developed a groundbreaking platform technology based on our unique hyper-vesiculating outer membrane vesicle (OMV) technology. This combined with our unique extraction method enable high-yield cost-effective production of bio-industrials and therapeutics.
Our first product is a revolutionary broad-protective bacterial E. coli vaccine targeting poultry production. We have PoC for both the vaccine and an aerosol application method.
With E. coli being the single most important cause of mortality and infections in poultry, we will significantly reduce global consumption of antimicrobials, thereby minimizing antimicrobial resistance (AMR) development, improve animal welfare, and reduce CO2 emissions and food waste, while increasing customer profits.
With our excellent industry network and a strong demand for new vaccines, market entry barriers are low and the potential massive.
1
Innovative Platform Technology
BROAD-SPECTRUM APPLICATIONS
Gefjon Pharma’s platform technology is built on a genetically modified, hyper-productive, and patentable bacterial strain, enabling efficient and cost-effective protein expression. Combined with an optimized extraction and production process, this innovation supports a wide range of applications in both veterinary and human medicine.
2
E. coli vaccine for poultry
SEVEN CLINCAL TRIALS
Our initial product is an innovative broad-spectrum E. coli vaccine for poultry, developed using outer membrane vesicles. With a validated proof of concept for both the vaccine and an aerosol delivery system, it targets a leading cause of mortality and infection in poultry. By reducing reliance on antimicrobials, it improves animal welfare, decreases CO₂ emissions and food waste, and increases revenue opportunities for producers.
3
Research & Development
ONGOING RESEARCH PROJECTS
Gefjon Pharma is diligently exploring new applications for its platform technology through collaborative research and development projects with the University of Copenhagen. By consistently driving innovation, we aim to unlock new solutions in both veterinary and human medicine.
News
Gefjon Pharma has been awarded a GUDP - Grønt Udviklings & Demonstrationsprogram grant for the project ColiControl
December, 2024
Gefjon Pharma entered into an Innofounder agreement to accelerate the company’s development
June, 2024
Contact Us
Our Team
With over 75 years of combined experience in research, development, pharmaceutical production, business, and business development, our team brings diverse expertise and strong foundations for building successful companies.
Partners
Gefjon Pharma has been recognized and supported by several respected institutions, highlighting the significance and potential impact of our work.
Anders Miki Bojesen
Chief Scientific Officer
Co-founder
Fabio Antenucci
Chief Technology Officer
Co-founder
Thomas Buthler
Chief Operations & Quality Officer
Co-founder
Torben Hald
Chief Executive Officer
Co-founder